Financial Report: Abbott 4Q

Abbott
 
4Q Revenues: $8.0 billion (+10%)

4Q Earnings: $1.5 billion (+28%)

FY Revenues: $30.0 billion (+14%)

FY Earnings: $4.9 billion (+35%)

Comments: Worldwide pharmaceutical sales were up 10% to $4.6 billion in the quarter, and up 14% to $16.7 billion for the year, driven by Humira, Niaspan, and the TriCor/Trilipix franchise. Humira sales in the quarter were $1.4 billion (+41%) and $4.5 billion for the year (+48%). TriCor/Trilipix sales in the quarter were $455 million (+16%) and $1.3 billion for the year (+10%). Niaspan span sales in the quarter were $221 million (+24%) and $786 million for the year (+19%). Depakote sales in the quarter were down 42% to $268 million, due to generic competition. U.S. Pharmaceutical sales were $2.5 billion in the quarter (+10%) and $8.5 billion for the year (+9%). Worldwide medical products sales increased 16% in the quarter, with 59% growth in global vascular sales driven by Xience V.